INDIANAPOLIS--(BUSINESS WIRE)--Scioto Biosciences, a preclinical stage company developing next generation microbiome therapeutics, today announced that it will present at the Microbiome Movement - Maternal & Infant Health Summit held on May 22-24th at the Revere Boston Common Hotel.
Dr. Mark Heiman, Chief Scientific Officer of Scioto will give a talk on May 24th at 9:30 a.m., titled “Spontaneous Weaning of Rat Pups is Stimulated by SB-121 - mediated Gut Development,” which will highlight the company's unique live bacterial therapeutic platform formulation SB-121 and its benefits in promoting the development of a healthy infant microbiome. By delivering live bacteria in the activated state, Scioto’s platform promotes colonization and provides lasting beneficial effects of the active bacteria lactobacillus reuteri. Studies in premature animals have shown the ability to alter the microbiome and provide enhanced efficacy with just a single dose of bacteria.
“Our novel Activated Bacterial Therapeutic (ABT) delivery platform provides enhanced function for live bacterial therapeutics. This will be a tremendous benefit to patients, including the neonatal population,” explained Heiman. “With this unique platform, we can take an off-the-shelf, commensal bacteria like lactobacillus reuteri and create a pipeline to treat multiple patient populations.”
Microbiome Movement - Maternal & Infant Health Summit is the industry-leading forum that focuses exclusively on the development and commercialization of microbiome-based therapeutics for Maternal & Infant Health; with case-studies from target discovery all the way through to clinical trial development, manufacturing and beyond.
About Scioto Biosciences
Based in Indianapolis, Scioto Biosciences is a preclinical stage company developing innovative therapies devoted to having a transformative impact on the delivery of live bacterial therapeutics (LBTs). Scioto was founded in 2017 as a partnership between Indiana business accelerator, Monon Bioventures (MBV) and The Research Institute at Nationwide Hospital (RINCH), with whom the company has a worldwide exclusive licensing agreement. The Scioto ABT delivery platform has the potential to enhance efficacy wherever LBTs are used such as metabolic disease, neurological disorders, gastrointestinal health, alternatives to in-feed antibiotics (in livestock) and others. For more information, visit http://sciotobiosciences.com/.
